This case was transformed to SCLC after treatment of a first-generation EGFR TKIs, and the combination treatment modality (chemotherapy, target therapy and immunotherapy) with anlotinib was continued in the subsequent treatment, which enabled this patient to have an OS of more than 20 months after transformation to SCLC. This evidence concerns the gene EGFR and small cell lung carcinoma.